Sacubitril/valsartan: A practical guide

Cândida Fonseca, Dulce Brito, Jorge Ferreira, Fátima Franco, João Morais, José Silva Cardoso

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


© 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70% of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.
Original languageEnglish
JournalRevista Portuguesa de Cardiologia
Publication statusPublished - May 2019


  • Heart failure with reduced ejection fraction
  • Practical guidance
  • Sacubitril/valsartan


Dive into the research topics of 'Sacubitril/valsartan: A practical guide'. Together they form a unique fingerprint.

Cite this